BioAlliance Pharma: Strengthening And Extension Of The Industrial Protection Of Livatag® Until 2031
2/18/2014 10:11:12 AM
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products, announced today a major strengthening of the patent protection for its product Livatag® (doxorubicine Trandrug™), currently in phase III clinical trial in primary liver cancer (ReLive trial).
Help employers find you! Check out all the jobs and post your resume.
comments powered by